Discovering therapeutic antibodies designed by nature

AIMM’s fully human monoclonal antibody pipeline

Utilizing its AIMSelect™ and AIMProve™ platforms AIMM has developed a pipeline of novel antibodies to treat diseases with high unmet medical need for which a clear clinical development path has been established. AIMM’s current focus is on cancer. Earlier programs that targeted infectious diseases have produced first-in-class and best-in-class antibodies that currently are in clinical Phase 1 and Phase 2 as well as late stage preclinical development.

Updated July 2017

AIMM’s fully human mAb pipeline

AIMM’s fully human mAb pipeline